Incyte Corp

9. Okt. 2026, 20:07 UTC

Incyte Corp shares traded roughly flat, peaking at a cumulative return of 0.90%, but remain significantly below their 20-day moving average.

8. Okt. 2026, 20:07 UTC

RBC Capital raised Incyte's price target to $114 and maintained its Sector Perform rating ahead of the company's Q3 results on October 29, 2026.

7. Okt. 2026, 21:31 UTC

Incyte Corp is trading lower in after-market hours, closing at its lowest point of the day and below its 20-day moving average.

6. Okt. 2026, 19:50 UTC

Incyte Corp shares fell sharply, extending a six-session decline amid notable volatility, with current prices significantly below the 20-day moving average.

5. Okt. 2026, 21:01 UTC

Incyte Corp is down significantly in after-market trading, marking its seventh consecutive session lower and remaining well below its 20-day moving average.

2. Okt. 2026, 23:05 UTC

Incyte Corp saw a modest increase in after-market trading, reaching its highest level since Friday's close, despite notable volatility during the session.

1. Okt. 2026, 23:15 UTC

Incyte Corp declined in after-market hours, marking its fourth consecutive session of losses and remaining significantly below its 20-day moving average.

30. Sept. 2026, 20:01 UTC

Incyte Corp shares fell sharply, remaining below their 20-day moving average and positioned near the lower end of their one-month range.

29. Sept. 2026, 20:07 UTC

Incyte Corp's shares fell sharply, reaching a midday low and finishing weaker, remaining below their 20-day moving average and near the lower end of their one-month trading range.

28. Sept. 2026, 21:01 UTC

Incyte Corp has advanced in after-market trading, reaching its highest level for the session amid broader biotechnology sector activity and remaining above its 20-day moving average.

25. Sept. 2026, 19:36 UTC

Incyte shares fell after FDA approved Atebrioz for fibrodysplasia ossificans progressiva, as traders await clarity on the drug's commercial prospects.

24. Sept. 2026, 22:01 UTC

Incyte Corp declined significantly in after-market trading, remaining well below its 20-day moving average and near the lower end of its one-month range.

23. Sept. 2026, 20:07 UTC

Incyte Corp shares are declining, despite social media highlighting its strength in the biotechnology sector, reflecting a cumulative decline since Tuesday's close.

22. Sept. 2026, 23:45 UTC

Incyte Corp is trading modestly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month range.

21. Sept. 2026, 20:06 UTC

Incyte Corp's shares are declining despite announcing an expanded partnership with Specialised Therapeutics to commercialize ruxolitinib cream in Australia.

18. Sept. 2026, 22:51 UTC

Incyte Corp is trading modestly higher in after-market hours, reflecting broader market trends amid mixed equity performance and rising treasury yields.

17. Sept. 2026, 23:26 UTC

Incyte Corp's stock is trading higher in after-market hours as investors await an FDA decision on zilurgisertib, with a target date of September 26.

16. Sept. 2026, 23:06 UTC

Incyte Corp is trading lower in after-market hours, marking its lowest point since the market closed and remaining below its 20-day moving average.

15. Sept. 2026, 23:06 UTC

Incyte Corp shares are trading lower in after-market hours, reflecting broader market fluctuations and remaining below the 20-day moving average.

14. Sept. 2026, 20:08 UTC

Incyte Corp's shares are higher amid overall market gains, despite earlier volatility. Broader market concerns include rising crude oil prices and inflation.

11. Sept. 2026, 22:01 UTC

Incyte Corp shares are higher in after-market trading, despite a decline in consumer sentiment reflected by the Michigan Consumer Sentiment Index.

10. Sept. 2026, 19:36 UTC

Incyte's MINJUVI receives funding in Ontario for lymphoma treatment. Shares are lower despite this development, currently trading below their 20-day moving average.

9. Sept. 2026, 19:07 UTC

Incyte Corp gains amid positive sentiment for its upcoming PDUFA date for Zilurgisertib, scheduled for September 26, despite earlier session volatility.

8. Sept. 2026, 20:02 UTC

Incyte Corp shares are lower today, driven by a downturn in the Biotechnology sub-sector. Analysts maintain a consensus "Moderate Buy" rating on the stock.

4. Sept. 2026, 23:55 UTC

Incyte Corp shares are higher in after-market hours, reaching an early peak before settling back. No specific news was identified to explain the movement.

3. Sept. 2026, 19:16 UTC

Incyte Corp shares are lower amid broader market declines influenced by rising jobless claims. The stock remains above its 20-day moving average.

2. Sept. 2026, 23:16 UTC

Incyte Corp shares are trading higher in after-market hours, amid a weaker-than-expected ADP payrolls report that may influence Federal Reserve interest rate decisions.

1. Sept. 2026, 22:06 UTC

Incyte Corp shares are higher in after-market hours, though no specific news explains the movement. Broader market pressures persist from rising bond yields.

31. Aug. 2026, 20:04 UTC

Incyte Corp shares are lower amid broader market weakness following comments from Warsh at the Jackson Hole Economic Symposium on inflation and monetary policy.

28. Aug. 2026, 23:21 UTC

Incyte Corp shares are lower in after-market trading, continuing a trend of four consecutive sessions finishing down amid rising Treasury yields and mixed ESMO data sentiment.